Results 91 to 100 of about 169,740 (340)
Aliskiren, enalapril, or aliskiren and enalapril in heart failure [PDF]
BACKGROUND Among patients with chronic heart failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown.
] +15 more
core +5 more sources
Intraosseous sarcoidosis imitating peri‐implantitis: A case study
Abstract Background Sarcoidosis is a multisystem granulomatous disorder of unknown cause, typically affecting the lungs and lymph nodes, but it can also involve the eyes, skin, heart, bones, and other organs. The exact cause is unclear, but genetic factors and environmental triggers like infections, chemicals, or dust may play a role.
Magdalena Orlowska +2 more
wiley +1 more source
ABSTRACT Background Advanced heart failure (HF) remains a clinical challenge, and mitral transcatheter edge‐to‐edge repair (M‐TEER) has emerged as a potential bridging strategy. Aims To describe the clinical outcomes of M‐TEER in a single‐center cohort of patients with advanced HF and to identify anatomical and clinical features potentially associated ...
Pedro Castilhos de Freitas Crivelaro +8 more
wiley +1 more source
Beta-blocker under-use in COPD patients [PDF]
Background: Cardiovascular (CVS) comorbidities are common in COPD and contribute significantly to morbidity and mortality, especially following acute exacerbations of COPD (AECOPD).
Lavender, Melanie +4 more
core +2 more sources
ABSTRACT Background Unfractionated heparin (UFH) remains the standard anticoagulant during percutaneous coronary intervention (PCI), with guidelines recommending a target activated clotting time (ACT) of ≥250 s. However, despite receiving a standardized bolus dose, many patients fail to achieve this target.
Manh Cuong Vu +9 more
wiley +1 more source
Angiotensin-converting enzyme inhibitors
More than 30 years since their discovery, angiotensin-converting enzyme (ACE) inhibitors still represent one of the most commonly prescribed medications for treating hypertension and one of the favored first-line agents, particularly in the presence of high-risk conditions, such as diabetes.
GENTILE, GIORGIO +4 more
openaire +5 more sources
Angiotensin blockade for diabetes: Monitor microalbuminuria? [PDF]
No studies address whether continued screening for microalbuminuria once a patient is taking an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-2 receptor blocker (ARB) improves outcomes.
Blenning, Carol E. +2 more
core
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon +10 more
wiley +1 more source
Resetting the neurohormonal balance in heart failure (HF). the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF [PDF]
The natriuretic peptide (NP) system, which includes atrial natriuretic peptide, B-type natriuretic peptide, and C-type natriuretic peptide, has an important role in cardiovascular homeostasis, promoting a number of physiological effects including ...
Rubattu, Speranza Donatella +1 more
core +2 more sources
The impact of the choice of common data model (CDM) approach on the study results in a real‐world evidence (RWE) study is unknown. We aimed to determine potential differences in the results of an RWE study when data were mapped to two different CDMs, ConcePTION and OMOP. With the same instance of CPRD GOLD, data were mapped to both CDMs. Using the same
Nicholas B. Hunt +8 more
wiley +1 more source

